Treating Acute Leukemias
in Europe
Emerging and Practical Concepts and Controversies in Leukemias
Overview
In recent years, progress in the understanding of acute leukemias has led to novel therapies that are rapidly changing treatment paradigms. Aptitude Health developed the Global Leukemia Academy to help physicians who treat acute leukemias bridge the gap between innovation and implementation for patient care.
Date and Location
27 – 28 October 2021, Virtual Meeting
Meeting Content
View the slides and watch the video of Day 1
Virtual Plenary Sessions
View the slides and watch the video of Day 2
Virtual Breakout: Adult Leukemia Patients
View the slides and watch the video of Day 2
Virtual Breakout: Pediatric ALL Patients
Ask your questions directly to the experts and receive their personal insights on current and novel treatment approaches for pediatric and adult patients with acute leukemias.
Faculty
Elias Jabbour, MD
MD Anderson Cancer Center,
USA
Franco Locatelli, MD, PhD
Sapienza, University of Rome
IRCCS Bambino Gesù Children’s Hospital,
Italy
Naval Daver, MD
MD Anderson Cancer Center,
USA
Patrick A. Brown, MD
Johns Hopkins University
School of Medicine, USA
Josep-Maria Ribera, MD, PhD
Catalan Institute of Oncology,
University Hospital Germans Trias i Pujol,
Spain
Rob Pieters, MD, PhD
Princess Máxima Center for Pediatric Oncology,
University of Utrecht, The Netherlands
Nicola Gökbuget, MD
University Hospital Frankfurt,
Germany
Christina Peters, MD
St. Anna Children’s Hospital,
Vienna, Austria
Charles Craddock, CBE, FRCP (UK), FRCPath, DPhil
Centre for Clinical Haematology at the Queen Elizabeth Hospital,
Birmingham, UK
Philippe Rousselot, MD, PhD
University of Versailles Saint-Quentin-en-Yvelines,
France
Martin Schrappe MD, Prof
University Medical Center Schleswig-Holstein,
Germany
Richard F. Schlenk, MD, Prof
University of Heidelberg, Germany
|
Agenda |
This 2-day interactive virtual meeting with global experts will focus on the management of acute leukemia patients in Europe. Day 1: Follow presentations, interact with the faculty in a debate on sequencing CD19-targeted approaches, monoclonal antibodies, and bispecifics vs CAR T, and hear a panel discussion on optimal treatment and patient access, and regional challenges in Europe Day 2: Join the pediatric ALL or the adult leukemia breakout session to learn about treatment strategies for newly diagnosed and relapsed/refractory acute leukemia patients, and attend the patient case-based panel discussions focusing on toxicity management |
Day 1 – VIRTUAL PLENARY SESSIONS Wednesday, October 27, 2021
Chairs – Elias Jabbour, Franco Locatelli, Naval Daver
16.00 – 20.00 CEST (Central European Standard Time)
| Time CEST | Topic | Presenter |
| 16.00 – 16.10 | Welcome and meeting overview • Introduction to the voting system |
Elias Jabbour, Franco Locatelli |
| 16.10 – 16.40 | Recent developments in acute leukemias | Elias Jabbour |
| 16.40 – 17.00 | Review of prognostic value of MRD in acute leukemias | Josep-Maria Ribera |
| 17.00 – 17.15 | Genetic variants in ALL – Ph+ and Ph-like | Philippe Rousselot |
| 17.15 – 17.30 | AYA ALL patients – what is the current treatment approach for this diverse patient population? | Rob Pieters |
| 17.30 – 17.45 | Break | |
| 17.45 – 18.05 | Bispecifics as post-reinduction therapy improve survival in high-risk first-relapse pediatric and AYA B-ALL |
Patrick Brown |
| 18.05 – 18.25 | Therapeutic approaches in high-risk and older AML patients | Naval Daver |
| 18.25 – 18.45 | Current and future role of transplantation in acute leukemias | Charles Craddock |
| 18.45 – 19.15 |
Debate on sequencing CD19-targeted approaches • Monoclonal antibodies and bispecifics first (10 min) |
Moderator: Franco Locatelli Elias Jabbour Josep-Maria Ribera All faculty |
| 19.15 – 19.55 | Leukemia board discussion • Optimal treatment and patient access, regional challenges in Europe – West/East perspective (5 + 5 min) • Discussion (20 min) • Case presentation (5 min) and discussion (10 min) |
Moderator: Elias Jabbour Richard Schlenk and Philippe Rousselot Case from local physician All faculty |
| 19.55 – 20.00 | Session close | Elias Jabbour, Franco Locatelli |
Day 2 – VIRTUAL BREAKOUT: ADULT LEUKEMIA PATIENTS Thursday, October 28, 2021
Chairs – Elias Jabbour, Naval Daver
17.00 – 20.00 CEST (Central European Standard Time)
| Time CEST | Topic | Presenter |
| 17.00 – 17.10 | ALL session open • Educational ARS questions for the audience |
Elias Jabbour |
| 17.10 – 17.30 | Optimizing first-line therapy in adult and older ALL – integration of immunotherapy into frontline regimens • Presentation (15 min) + Q&A (5 min) |
Elias Jabbour |
| 17.30 – 17.50 | Current treatment options for relapsed ALL in adult and elderly patients • Presentation (15 min) + Q&A (5 min) |
Nicola Gökbuget |
| 17.50 – 18.20 |
Case-based panel discussion on toxicity management for adult and elderly ALL patients • Case 1 presentation (5 min) + discussion (10 min) |
Moderator: Elias Jabbour Case from local physicians Faculty panel: E. Jabbour, N. Gökbuget, J.M. Ribera, P. Rousselot |
| 18.20 – 18.30 | Break | |
| 18.30 – 18.35 | AML session open | Naval Daver |
| 18.35 – 18.55 | Personalized induction and maintenance approaches for AML • Presentation (15 min) + Q&A (5 min) |
Richard Schlenk |
| 18.55 – 19.15 | Optimizing management of relapsed/refractory AML • Presentation (15 min) + Q&A (5 min) |
Charles Craddock |
| 19.15 – 19.45 |
Case-based panel discussion or questions to the panel on regional challenges in AML care • Case 1 presentation (5 min) + discussion (10 min) |
Moderator: Naval Daver Cases from local physicians Faculty panel: N. Daver, C. Craddock, R. Schlenk |
| 19.45 – 20.00 | Session close • Educational ARS questions for the audience |
Elias Jabbour |
Day 2 – VIRTUAL BREAKOUT: PEDIATRIC ALL PATIENTS Thursday, October 28, 2021
Chair – Franco Locatelli
17.00 – 19.45 CEST (Central European Standard Time)
| Time CEST | Topic | Presenter |
| 17.00 – 17.15 | Session open • Educational ARS questions for the audience |
Franco Locatelli |
| 17.15 – 17.40 | How to use MRD and genetics for risk stratification and therapy guidance in pediatric ALL • Presentation (15 min) + Q&A (10 min) |
Rob Pieters |
| 17.40 – 18.05 | First-line treatment of pediatric ALL • Presentation (15 min) + Q&A (10 min) |
Martin Schrappe |
| 18.05 – 18.30 | Current treatment options for relapsed ALL in children, including HSCT considerations • Presentation (15 min) + Q&A (10 min) |
Franco Locatelli |
| 18.30 – 18.55 | Bispecific T-cell engagers for pediatric ALL • Presentation (15 min) + Q&A (10 min) |
Christina Peters |
| 18.55 – 19.25 |
Case-based panel discussion on management of long- and short-term toxicities in pediatric ALL patients • Case presentation 1 Francesca Del Bufalo (department Franco Locatelli) (5 min) + discussion (10 min) |
Moderator: Franco Locatelli Case from local physicians Faculty panel: R. Pieters, F. Locatelli, P. Brown, M.Schrappe, C. Peters |
| 19.25 – 19.45 | Final discussion, Q&A, and session close • Educational ARS questions for the audience |
Franco Locatelli |
